Trial · NCT01342952
Results by group373
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 373
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) | Ambrisentan 2.5 mg (Safety) | Non-STEAEs | 3 | Participants | |
| Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) | Ambrisentan 5 mg (Safety) | Non-STEAEs | 13 | Participants | |
| Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) | Ambrisentan 7.5 mg (Safety) | Non-STEAEs | 5 | Participants | |
| Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) | Ambrisentan 10 mg (Safety) | Non-STEAEs | 10 | Participants | |
| Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) | Ambrisentan 2.5 mg (Safety) | STEAEs | 2 | Participants | |
| Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) | Ambrisentan 5 mg (Safety) | STEAEs | 7 | Participants | |
| Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) | Ambrisentan 7.5 mg (Safety) | STEAEs | 4 | Participants | |
| Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) | Ambrisentan 10 mg (Safety) | STEAEs | 8 | Participants | |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 2.5 mg (Safety) | ALT | -7.5 | Standard Deviation 12.56 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 5 mg (Safety) | ALT | -1.0 | Standard Deviation 8.64 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 7.5 mg (Safety) | ALT | 0.8 | Standard Deviation 4.09 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 10 mg (Safety) | ALT | 4.0 | Standard Deviation 7.42 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 2.5 mg (Safety) | AST | -11.8 | Standard Deviation 6.29 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 5 mg (Safety) | AST | -5.6 | Standard Deviation 7.23 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 7.5 mg (Safety) | AST | -1.0 | Standard Deviation 2.55 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 10 mg (Safety) | AST | -2.1 | Standard Deviation 8.13 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 2.5 mg (Safety) | GGT | -0.5 | Standard Deviation 15.00 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 5 mg (Safety) | GGT | -7.0 | Standard Deviation 10.45 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 7.5 mg (Safety) | GGT | -0.8 | Standard Deviation 8.44 | Millimoles per liter |
| Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin | Ambrisentan 10 mg (Safety) | GGT | -4.6 | Standard Deviation 28.30 | Millimoles per liter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01342952/results